New antibody drug aims to prevent strokes in irregular heartbeat
NCT ID NCT07626411
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This large phase 3 trial tests an experimental drug, REGN7508, against the standard blood thinner apixaban for preventing strokes in people with atrial fibrillation (an irregular heartbeat). The study will enroll over 15,000 participants to compare how well each drug prevents strokes and serious bleeding. The goal is to see if REGN7508 is a safe and effective alternative.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- REGN7508 (cenvacibart), a monoclonal antibody
- What this could lead to
- If successful, this could offer a new, potentially safer option for preventing strokes in people with atrial fibrillation.
- What could go wrong
- This is a large phase 3 trial, but the drug is still experimental. It may not prove safer or more effective than apixaban, and there is a risk of unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a smartphone alert replace daily blood thinners for AF?
- A tiny neck implant could catch Stroke-Causing clots before they reach the brain
- Blood fat clues could flag hidden heart rhythm risk
- Could a new injection tame atrial fibrillation?
- Can a new heart ablation technique work without x-rays?
- Which blood thinner is safer for heart patients? a Head-to-Head test